Lorena Lewy-Alterbaum, MD
Endocrinology, Diabetes & Metabolism · Hollywood, FLNPI 1184789943
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $21,233 of the $24,945 with a category attached, or 85.1%. 41 manufacturers reported payments, led by Eli Lilly at 51.0% of the total. 2025 is the largest year on record at $14,599, 9.4 times the $1,557 reported in 2019.
Across 606 payments — averaging $41.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$13K
- Novo Nordisk$2K
- Novartis$2K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$742
- Insulet Corporation$732
- plus $6K from 35 others
Across 481 payments — averaging $6466.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.6M
- AbbVie$706K
- Applied Therapeutics, Inc.$243K
- AstraZeneca$185K
- Braintree Laboratories, Inc.$164K
- Sanofi US Services Inc.$86K
- plus $144K from 6 others
What the payments were for
- Speaking & faculty fees$2501%
- Travel & lodging$3,32813%
- Food & beverage$21,23385%
- Education$460%
- Gifts$870%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$250
- Tresiba$187
- FARXIGA$125
- Ozempic$125
- Omnipod$125
How this compares
$24,945 in reported general payments places this provider in the 85th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 252 | $311,171 |
| MounjaroTirzepatide | 190 | $257,230 |
| JardianceEmpagliflozin | 95 | $102,138 |
| TrulicityDulaglutide | 50 | $72,501 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $51,392 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 32 | $38,708 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $34,814 |
| KerendiaFinerenone | 32 | $34,518 |
| Tresiba Flextouch U-100Insulin Degludec | 47 | $34,148 |
| JanuviaSitagliptin Phosphate | 28 | $31,378 |
| FarxigaDapagliflozin Propanediol | 27 | $22,440 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 22 | $21,875 |
| TradjentaLinagliptin | 24 | $21,242 |
| SynthroidLevothyroxine Sodium | 200 | $20,984 |
| RybelsusSemaglutide | 17 | $18,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,826 | $339,622301 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,439 | $329,731240 claims |
| Boehringer IngelheimJardiance, Tradjenta | $742 | $123,381119 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $633 | $38,70832 claims |
| BayerKerendia | $111 | $34,51832 claims |
| MerckJanuvia | $251 | $31,37828 claims |
| AstraZenecaFarxiga | $248 | $22,44027 claims |
| AbbVieSynthroid | $151 | $20,984200 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $359 | $4,066285 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Hollywood
- Paul JellingerHollywood$159K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.